News | Oncology Related Products | March 15, 2016

Company regains full ownership, including royalties on BSD-2000 Hyperthermia System

Pyrexar, buy back outside ownership, Person Medical, BSD-2000 Hyperthermia System

BSD-2000 image courtesy of Pyrexar Medical


March 15, 2016 — Pyrexar announced it has purchased back outside ownership from Person Medical (formerly BSD Medical), concluding a purchase agreement made by the two companies in 2015.

In the original agreement, Pyrexar purchased the hyperthermia device group from Person. In exchange, Person Medical acquired 19.9 percent of Pyrexar, along with royalties on future sales of the BSD-2000 Hyperthermia System, Pyrexar’s flagship product. The royalties were valued at an estimated $4 million over the next three years.

Pyrexar announced several other business developments, including:  

  • New distribution — The company added nine new international distribution companies, with several more in negotiation to bring sales coverage to 31 countries;
  • Revamped manufacturing workflow — The company increased the speed of its manufacturing process by 600 percent;
  • Regulatory process — The company added Taiwan Food and Drug Administration (TFDA), Korean FDA, TUV Rheinland and Restriction of Hazardous Substances Directive (RoHs) compliance to their process; and
  • Engineering updates — Manufacturing processes are being re-engineered to be more efficient and cost effective. The company is also exploring new thermal therapy products.

For more information: www.pyrexar.com

Related Content

News | Interventional Radiology

Varian announced it has signed an asset purchase agreement to acquire the Boston Scientific portfolio of drug-loadable microsphere and bland embolic bead products for treating arteriovenous malformations and hypervascular tumors. When completed, this acquisition, in combination with the recent acquisitions of Endocare and Alicon, will expand Varian's portfolio of multidisciplinary integrated cancer care solutions.

Time July 03, 2019
arrow
Technology | Focused Ultrasound Therapy

Insightec announced that the U.S. Food and Drug Administration (FDA) has approved an expansion of the indication of Exablate Neuro to include the treatment of patients with tremor-dominant Parkinson's disease (PD).

Time December 21, 2018
arrow
Videos | Radiation Oncology

Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation ...

Time November 06, 2018
arrow
News | Radiation Dose Management

AngioDynamics Inc. announced an agreement to acquire RadiaDyne, a privately held medical diagnostic and device company that designs and develops patient dose monitoring technology to improve cancer treatment outcomes.

Time September 24, 2018
arrow
News | Radiation Oncology

World Cancer Day takes place annually on Feb. 4 to raise awareness and education in the media, governments and people ...

Time February 01, 2018
arrow
News | Oncology Related Products

December 19, 2016 — Children’s National Health System and Celsion Corp. announced in November the launch of a clinical ...

Time December 19, 2016
arrow
News | Clinical Decision Support

October 27, 2016 — The National Comprehensive Cancer Network (NCCN) continues to build its library of appropriate use ...

Time October 27, 2016
arrow
News | Ultrasound Imaging

September 12, 2016 — Tiny microbubbles are being used to more effectively identify liver tumors, according to a study ...

Time September 12, 2016
arrow
Feature | Cardio-oncology | Dave Fornell

Cardio-oncology is an emerging field that combines the expertise of both cardiology and oncology to assess and treat ...

Time May 13, 2016
arrow
News | Oncology Related Products

May 6, 2016 — After breast cancer surgery, women are prescribed adjuvant (or follow-up) therapies such as chemotherapy ...

Time May 06, 2016
arrow
Subscribe Now